Engineering the next-generation of programmable advanced therapies

RNAi taken to the next level

Gene Editing induced Gene Silencing (GEiGS) uses universal gene editing tools to minimally edit the host’s own non-coding genes and redirect their silencing activity (RNAi) towards any desired target gene or gene family.

Our cutting edge bioinformatics platform designs gene editing solutions to allow precise and effective implementation of GEiGS technology, ensuring cell type- or condition-specific activity.

GEiGS^® targets endogenous or exogenous genes

Key advantages of GEiGS^®

Stable, Tunable and Programmable gene silencing functionality

GEiGS requires only minimal changes to the cells genome, thus avoiding epigenetic inactivation and allowing for highly stable RNAi activity. Silencing activity is tuned through non-coding RNA selection and engineering, and through controlling sequence complementarity, utilising the cells native regulatory machinery to achieve programmable functionality.
Compatible with autologous and allogeneic (iPSC & donor derived) product development

GEiGS technology has been demonstrated in both iPSC-derived and primary cell contexts, enabling implemention for autologous and allogeneic product development.

For iPSC derived products, editing of non-coding genes is carried out in iPSCs prior to differentiation, allowing efficient gene editing workflows and assessment of off-target profiles, while avoiding limitations associated with autologous products such as cost-of-goods and scalability.
Attractive regulatory profile

In contrast to many other cell engineering approaches, gene modifications used are minimal and do not require stable incorporation of non-human sequences.
Universal platform that works with existing gene editing tools

GEiGS can be deployed by using a broad range of different nucleases, providing freedom to choose which gene editing tools to utilise based on the specific project, application and targeting requirements.

Stable and Tunable

GEiGS offers the ability to control gene expression with unprecedented precision. Our computational platform recodes endogenous miRNAs enabling a wide dynamic range of gene silencing activity.

Screening of engineered miRNAs through ectopic expression allows identification of preferred constructs prior to full GEiGS implementation via gene editing. Minimal gene edits in both iPSC and Primary T-cells demonstrate high efficiency mono and bi-allelic silencing and highly homogenous target expression profiles.

Programmable

GEiGS allows programmable gene silencing activity. Utilising state of the art in-vitro and in-vivo models, we are able to profile miRNA expression patterns to identify miRNAs specifically expressed in a given cell type and state. These are prioritised for recoding, allowing us to introduce GEiGS edits only active in the selected condition, as exemplified by monocyte/macrophage specific gene silencing.

Specific

GEiGS is highly specific. Minimal gene edits, redundancy in miRNA function, control of allelic editing copy number, and physiological expression results in no detectable gain or loss of function off-target effects in GEiGS-engineered iPSC lines.